Altimmune (ALT) Plummets 27% Despite Positive Clinical Data
Altimmune (ALT) fell 27% despite release positive clinical data in their non-alcoholic fatty liver disease (NAFLD) trial. Altimmune’s drug candidate reached its primary endpoint of a significant reduction in liver fat across all dose groups, as well as their secondary endpoint, of mean weight losses of 4.9% in patients without diabetes and 4.4% in patients with diabetes.
Principal Investigator Dr. Stephen Harrison said the following about the results in a press release:
“The marked decreases in both liver fat and serum ALT, together with approximately 5% weight loss in just 12 weeks in this NAFLD patient population, highlight pemvidutide as potentially a promising therapeutic for both NASH and obesity.”
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.